Peptide library / Cagrilintide

Cagrilintide

Cagrilintide is an investigational long-acting amylin analog studied alone and with semaglutide for weight management.

Peptide & blend guide

The short version

Why people discuss it
Discussed for satiety, appetite suppression and weight management. Community interest does not establish benefit or a suitable treatment.
What it is
Cagrilintide is an investigational long-acting amylin analog studied alone and with semaglutide for weight management.
Biggest caution
Results for cagrilintide alone and fixed-combination CagriSema are different evidence. FDA states that cagrilintide is not a component of an approved drug and cannot be used in compounding under federal law.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Sources report different amounts or schedules; the reference below is a named example, not a consensus.

Subcutaneous injection in trials and community discussion

Community reference · Not clinical guidance
Amount
0.25 mg initiation
Frequency
Once weekly
Duration / phase
First 4 weeks before trial-style escalation

Investigational trial pattern; no approved public-use regimen Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library